Back to the search results

Universitätsklinikum Hamburg-Eppendorf

Martinistraße 52
20246 Hamburg

Phone: 040-7410-0
Fax: 040-7410-54647
Mail: ed.eku@ofni

  • Number of beds: 1.526
  • Number of specialist departments: 36
  • Number of inpatient cases: 65.338
  • Number of partial inpatient cases: 5.897
  • Number of outpatient cases: 235.631
  • Number of cases of inpatient-equivalent psychiatric treatment (StäB): 17
  • Hospital owners: Freie und Hansestadt Hamburg
  • Type of provider: öffentlich
  • University Hospital
  • Academic teaching hospital
External comparative quality assurance
Further information
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung yes
  • Quality of participation in the Disease Management Programme (DMP)
    No participation
Quantity performed 39
Exception? No exception
Quantity performed 50
Exception? No exception
Quantity performed 144
Exception? No exception
Quantity performed 65
Exception? No exception
Quantity performed 76
Exception? No exception
Quantity performed 418
Exception? No exception
Overall result forecast presentation: yes
Quantity performed reporting year: 39
Quantity forecast year: 62
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 50
Quantity forecast year: 46
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 144
Quantity forecast year: 151
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 65
Quantity forecast year: 70
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 76
Quantity forecast year: 76
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 418
Quantity forecast year: 313
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 50
Quantity forecast year: 44
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
No. Explanation
CQ03 Quality assurance measures for the implementation of positron emission tomography (PET) in hospitals for the indications non-small-cell lung cancer (NSCLC) and solid pulmonary nodules
CQ05 Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ02 Quality assurance measures for the inpatient care of children and adolescents with haemato-oncological diseases
CQ24 Quality assurance measures for allogeneic stem cell transplantation for multiple myeloma (valid until 30 June 2022)
  • Clarifying chat completed: no
  • Clarifying chat not completed: no
  • No participation in clarifying chat: no
  • Notification of non-fulfilment of nursing care not made: yes
Number Group
841 Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
298 Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
284 Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations
* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

  • Is a protection concept in place? No
Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.
  • Drug commission

Verschiedene Dokumente im QM-Handbuch (QMH) des UKE. Stand: 04.10.2023

31.10.2021

SOP: 6.4.2 Verkehr mit Arzneimitteln

19.06.2020

  • Bereitstellung einer geeigneten Infrastruktur zur Sicherstellung einer fehlerfreien Zubereitung
  • Zubereitung durch pharmazeutisches Personal
  • Anwendung von gebrauchsfertigen Arzneimitteln bzw. Zubereitungen
  • Vorhandensein von elektronischen Systemen zur Entscheidungsunterstützung (z.B. Meona®, Rpdoc®, AIDKlinik®, ID Medics® bzw. ID Diacos® Pharma)
  • Versorgung der Patientinnen und Patienten mit patientenindividuell abgepackten Arzneimitteln durch die Krankenhausapotheke (z.B. Unit-Dose-System)
  • Fallbesprechungen
  • Maßnahmen zur Vermeidung von Arzneimittelverwechslung
  • Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
  • Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
  • Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
  • Aushändigung von Patienteninformationen zur Umsetzung von Therapieempfehlungen
  • Aushändigung des Medikationsplans
  • bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten
The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of ​​application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.
AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.
Job
Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Training in other healing professions
Comment

HB01 u. HB02 insgesamt: 349 Ausbildungsplätze

Comment

HB01 u. HB02 insgesamt: 349 Ausbildungsplätze

Comment

27 Ausbildungsplätze

Comment

43 Ausbildungsplätze

Comment

6 Ausbildungsplätze

Dr. jur. Monika Hartges

UKE Ombudsperson

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55384
Mail: ed.eku@nenosrepsdubmo

Arne Bräuner

UKE Ombudsperson

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55384
Mail: ed.eku@nenosrepsdubmo

Frau Hilke Holsten-Griffin

Lob- und Beschwerdemanagement

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-57985
Mail: ed.eku@gnuniem-erhi

Frau Beate Gerber

Lob- und Beschwerdemanagement

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-57985
Mail: ed.eku@gnuniem-erhi

Dr. Hans-Jürgen Bartz

Geschäftsbereichsleiter QM und klin. Prozessmanagement

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-56048
Mail: ed.eku@ztrab.h

Prof. Dr. Burkhard Göke

Ärztlicher Direktor

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55001
Mail: ed.eku@ekeog

Prof. Dr. Christian Gerloff

Ärztlicher Direktor

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55001
Mail: ed.eku@ffolreg

Dr. Michael Baehr

Leiter Klinikapotheke

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-52086
Mail: ed.eku@rheab

Dipl.- Ing. Silvia Braun

Arbeitgeberbeauftragte

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-57258
Mail: ed.eku@nuarb.s

Martinistraße 52
20246 Hamburg

Phone: 040-7410-0
Fax: 040-7410-54647
Mail: ed.eku@ofni

M. A. Joachim Prölß

Direktor für Patienten- und Pflegemanagement

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-53850
Mail: ed.eku@ssleorp.j

Marya Verdel

Kaufmännische Direktorin

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-59000
Mail: ed.eku@ledrev.m

Dr. med. Martin Holder

Leiter Medizincontrolling

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-54503
Mail: ed.eku@redloh.m

Prof. Dr. Burkhard Göke

Ärztlicher Direktor

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55001
Mail: ed.eku@ekeog

Prof. Dr. Christian Gerloff

Ärztlicher Direktor

Martinistraße 52
20246 Hamburg

Phone: 040 -7410-55001
Mail: ed.eku@ffolreg

IK: 260200013

Location number: 773675000

Old location number: 773675000